PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
Status:
Completed
Trial end date:
2020-12-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of avelumab in patients with
metastatic neuroendocrine-like prostate cancer. Eligible men will be started on avelumab
every 2 weeks and will stay on therapy until progression or intolerable side effects. The
central hypothesis is that PD-L1 inhibition with avelumab will be efficacious based on
radiographic responses in a subset of men with metastatic neuroendocrine-like prostate cancer
and be reasonably well tolerated, meeting criteria for further study in larger phase 2 and 3
trials based on meeting pre-specified efficacy rates and prolonged PFS in some men.